KLRS
Kalaris Therapeutics Inc
Biotechnology
Market Cap$81M
5Y Perf.-46.1%
Build Your Comparison
Side-by-side financial analysisKLRS
ADMA
GRFS
REPL
Try popular comparisons:
Stock Comparison
KLRS vs ADMA vs GRFS vs REPL
Revenue, margins, valuation, and 5-year total return — side by side.
ADMA
ADMA Biologics, Inc.
Biotechnology
Market Cap$1.90B
5Y Perf.-58.6%
GRFS
Grifols, S.A.
Drug Manufacturers - General
Market Cap$6.46B
5Y Perf.+7.5%
REPL
Replimune Group, Inc.
Biotechnology
Market Cap$733M
5Y Perf.-8.9%
KLRS vs ADMA vs GRFS vs REPL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  KLRS |  ADMA |  GRFS |  REPL |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Drug Manufacturers - General | Biotechnology |
| Market Cap | $81M | $1.90B | $6.46B | $733M |
| Revenue (TTM) | $0.00 | $510M | $7.45B | — |
| Net Income (TTM) | $-44M | $165M | $416M | $-315M |
| Gross Margin | — | 61.3% | 37.7% | — |
| Operating Margin | — | 42.1% | 16.9% | — |
| Forward P/E | — | 9.9x | 8.9x | — |
| Total Debt | $1M | $80M | $8.74B | $76M |
| Cash & Equiv. | $98M | $88M | $825M | $111M |
KLRS vs ADMA vs GRFS vs REPL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KLRS
ADMA
GRFS
REPL
| Stock | Mar 25 | Jun 26 | Return |
|---|---|---|---|
| Kalaris Therapeutic… (KLRS) | 100 | 53.9 | -46.1% |
| ADMA Biologics, Inc. (ADMA) | 100 | 41.4 | -58.6% |
| Grifols, S.A. (GRFS) | 100 | 107.5 | +7.5% |
| Replimune Group, In… (REPL) | 100 | 91.1 | -8.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KLRS vs ADMA vs GRFS vs REPL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KLRS leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. ADMA Biologics, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. GRFS also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
🥇KLRS emerged as the overall leader. Track its performance:
KLRS
Kalaris Therapeutics Inc
The Defensive Pick
KLRS carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 0.81, Low D/E 1.8%, current ratio 12.23x
- Beta 0.81, current ratio 12.23x
- 100.0% revenue growth vs REPL's -39.7%
- Beta 0.81 vs ADMA's 1.11, lower leverage
Best for: sleep-well-at-night and defensive
ADMA
ADMA Biologics, Inc.
The Income Pick
ADMA is the #2 pick in this set and the best alternative if income & stability and growth exposure is your priority.
- Dividend streak 1 yrs, beta 1.11
- Rev growth 19.6%, EPS growth -25.9%, 3Y rev CAGR 49.0%
- 15.3% 10Y total return vs REPL's -41.4%
- 32.4% margin vs KLRS's -1.2%
Best for: income & stability and growth exposure
GRFS
Grifols, S.A.
The Value Play
GRFS is the clearest fit if your priority is value and dividends.
- Better valuation composite
- 2.7% yield; the other 3 pay no meaningful dividend
Best for: value and dividends
REPL
Replimune Group, Inc.
The Secondary Option
REPL lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  KLRS | 100.0% revenue growth vs REPL's -39.7% |
| Value |  GRFS | Better valuation composite |
| Quality / Margins |  ADMA | 32.4% margin vs KLRS's -1.2% |
| Stability / Safety | KLRS | Beta 0.81 vs ADMA's 1.11, lower leverage |
| Dividends | GRFS | 2.7% yield; the other 3 pay no meaningful dividend |
| Momentum (1Y) | KLRS | +56.9% vs ADMA's -62.0% |
| Efficiency (ROA) | ADMA | 27.4% ROA vs REPL's -72.2%, ROIC 36.0% vs -51.9% |
KLRS vs ADMA vs GRFS vs REPL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
FY 2025
Segment breakdown not available.
KLRS vs ADMA vs GRFS vs REPL — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLADMALAGGINGREPL
Who Leads Where
ADMA leads in 4 of 6 categories
GRFS leads 1 • KLRS leads 0 • REPL leads 0 • 1 tied
Explore the data ↓REPLReplimune Group, Inc.
0leads
KLRSKalaris Therapeutics …
0leads
GRFSGrifols, S.A.
1leads
ADMAADMA Biologics, Inc.
4leads
6 Total Categories
CATEGORYLEADERvs GRFSvs KLRSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ADMA5/6
Valuation MetricsMultiples, price ratios, and targets
GRFS5/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ADMA5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
ADMA4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
ADMA1/1
Income & Cash Flow (Last 12 Months)
ADMA leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
GRFS and KLRS operate at a comparable scale, with $7.4B and $0 in trailing revenue. ADMA is the more profitable business, keeping 32.4% of every revenue dollar as net income compared to GRFS's 5.6%.
| Metric | KLRSKalaris Therapeut… | ADMAADMA Biologics, I… | GRFSGrifols, S.A. |  REPLReplimune Group, … |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $510M | $7.4B | — |
| EBITDAEarnings before interest/tax | -$46M | $221M | $1.6B | -$323M |
| Net IncomeAfter-tax profit | -$44M | $165M | $416M | -$315M |
| Free Cash FlowCash after capex | -$49M | $108M | $745M | -$283M |
| Gross MarginGross profit ÷ Revenue | — | +61.3% | +37.7% | — |
| Operating MarginEBIT ÷ Revenue | — | +42.1% | +16.9% | — |
| Net MarginNet income ÷ Revenue | — | +32.4% | +5.6% | — |
| FCF MarginFCF ÷ Revenue | — | +21.2% | +10.0% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -0.3% | -3.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +81.7% | +72.7% | +25.3% | +2.5% |
ADMA leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
GRFS leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
At 11.6x trailing earnings, GRFS trades at a 15% valuation discount to ADMA's 13.7x P/E. On an enterprise value basis, GRFS's 8.3x EV/EBITDA is more attractive than ADMA's 9.5x.
| Metric | KLRSKalaris Therapeut… | ADMAADMA Biologics, I… | GRFSGrifols, S.A. | REPLReplimune Group, … |
|---|---|---|---|---|
| Market CapShares × price | $81M | $1.9B | $6.5B | $733M |
| Enterprise ValueMkt cap + debt − cash | -$16M | $1.9B | $15.6B | $698M |
| Trailing P/EPrice ÷ TTM EPS | -1.52x | 13.68x | 11.59x | -2.89x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 9.92x | 8.94x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 9.50x | 8.34x | — |
| Price / SalesMarket cap ÷ Revenue | — | 3.73x | 0.77x | — |
| Price / BookPrice ÷ Book value/share | 0.84x | 4.21x | 0.59x | 1.72x |
| Price / FCFMarket cap ÷ FCF | — | 68.40x | 7.44x | — |
GRFS leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
ADMA leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ADMA delivers a 39.0% return on equity — every $100 of shareholder capital generates $39 in annual profit, vs $-103 for REPL. KLRS carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to GRFS's 1.15x. On the Piotroski fundamental quality scale (0–9), GRFS scores 6/9 vs REPL's 2/9, reflecting solid financial health.
| Metric | KLRSKalaris Therapeut… | ADMAADMA Biologics, I… | GRFSGrifols, S.A. | REPLReplimune Group, … |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -72.8% | +39.0% | +5.4% | -102.7% |
| ROA (TTM)Return on assets | -43.5% | +27.4% | +2.1% | -72.2% |
| ROICReturn on invested capital | — | +36.0% | +5.4% | -51.9% |
| ROCEReturn on capital employed | -41.0% | +38.8% | +6.4% | -55.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 | 6 | 2 |
| Debt / EquityFinancial leverage | 0.02x | 0.17x | 1.15x | 0.18x |
| Net DebtTotal debt minus cash | -$97M | -$8M | $7.9B | -$35M |
| Cash & Equiv.Liquid assets | $98M | $88M | $825M | $111M |
| Total DebtShort + long-term debt | $1M | $80M | $8.7B | $76M |
| Interest CoverageEBIT ÷ Interest expense | -31.98x | 50.85x | 2.02x | -48.62x |
ADMA leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
ADMA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ADMA five years ago would be worth $44,620 today (with dividends reinvested), compared to $2,561 for REPL. Over the past 12 months, KLRS leads with a +56.9% total return vs ADMA's -62.0%. The 3-year compound annual growth rate (CAGR) favors ADMA at 28.5% vs REPL's -27.7% — a key indicator of consistent wealth creation.
| Metric | KLRSKalaris Therapeut… | ADMAADMA Biologics, I… | GRFSGrifols, S.A. | REPLReplimune Group, … |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -47.8% | -54.1% | -17.3% | -0.2% |
| 1-Year ReturnPast 12 months | +56.9% | -62.0% | -13.0% | -10.2% |
| 3-Year ReturnCumulative with dividends | -52.5% | +112.1% | -11.4% | -62.1% |
| 5-Year ReturnCumulative with dividends | -52.5% | +346.2% | -57.5% | -74.4% |
| 10-Year ReturnCumulative with dividends | -52.5% | +15.3% | -44.2% | -41.4% |
| CAGR (3Y)Annualised 3-year return | -22.0% | +28.5% | -3.9% | -27.7% |
ADMA leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — KLRS and GRFS each lead in 1 of 2 comparable metrics.
Risk & Volatility
KLRS is the less volatile stock with a 0.81 beta — it tends to amplify market swings less than ADMA's 1.11 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GRFS currently trades 68.6% from its 52-week high vs KLRS's 36.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KLRSKalaris Therapeut… | ADMAADMA Biologics, I… | GRFSGrifols, S.A. | REPLReplimune Group, … |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.81x | 1.11x | 0.99x | 0.84x |
| 52-Week HighHighest price in past year | $11.88 | $22.20 | $11.14 | $13.24 |
| 52-Week LowLowest price in past year | $2.14 | $7.21 | $7.26 | $1.50 |
| % of 52W HighCurrent price vs 52-week peak | +36.4% | +37.0% | +68.6% | +67.1% |
| RSI (14)Momentum oscillator 0–100 | 39.7 | 44.9 | 41.6 | 63.4 |
| Avg Volume (50D)Average daily shares traded | 86K | 5.0M | 551K | 8.9M |
Evenly matched — KLRS and GRFS each lead in 1 of 2 comparable metrics.
Analyst Outlook
ADMA leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: ADMA as "Buy", GRFS as "Buy", REPL as "Buy". Consensus price targets imply 331.2% upside for KLRS (target: $19) vs 57.7% for REPL (target: $14). GRFS is the only dividend payer here at 2.73% yield — a key consideration for income-focused portfolios.
| Metric | KLRSKalaris Therapeut… | ADMAADMA Biologics, I… | GRFSGrifols, S.A. | REPLReplimune Group, … |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $18.67 | $21.00 | — | $14.00 |
| # AnalystsCovering analysts | — | 10 | 8 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — | +2.7% | — |
| Dividend StreakConsecutive years of raises | — | 1 | 0 | 0 |
| Dividend / ShareAnnual DPS | — | — | $0.18 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.7% | +2.2% | 0.0% |
ADMA leads this category, winning 1 of 1 comparable metric.
Key Takeaway
ADMA leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). GRFS leads in 1 (Valuation Metrics). 1 tied.
Best OverallADMA Biologics, Inc. (ADMA)Leads 4 of 6 categories
Loading custom metrics...
KLRS vs ADMA vs GRFS vs REPL: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is KLRS or ADMA or GRFS or REPL a better buy right now?
For growth investors, ADMA Biologics, Inc.
(ADMA) is the stronger pick with 19. 6% revenue growth year-over-year, versus 0. 2% for Grifols, S. A. (GRFS). Grifols, S. A. (GRFS) offers the better valuation at 11. 6x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate ADMA Biologics, Inc. (ADMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — KLRS or ADMA or GRFS or REPL?
On trailing P/E, Grifols, S.
A. (GRFS) is the cheapest at 11. 6x versus ADMA Biologics, Inc. at 13. 7x. On forward P/E, Grifols, S. A. is actually cheaper at 8. 9x.
03Which is the better long-term investment — KLRS or ADMA or GRFS or REPL?
Over the past 5 years, ADMA Biologics, Inc.
(ADMA) delivered a total return of +346. 2%, compared to -74. 4% for Replimune Group, Inc. (REPL). Over 10 years, the gap is even starker: ADMA returned +15. 3% versus KLRS's -52. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — KLRS or ADMA or GRFS or REPL?
By beta (market sensitivity over 5 years), Kalaris Therapeutics Inc (KLRS) is the lower-risk stock at 0.
81β versus ADMA Biologics, Inc. 's 1. 11β — meaning ADMA is approximately 37% more volatile than KLRS relative to the S&P 500. On balance sheet safety, Kalaris Therapeutics Inc (KLRS) carries a lower debt/equity ratio of 2% versus 115% for Grifols, S. A. — giving it more financial flexibility in a downturn.
05Which is growing faster — KLRS or ADMA or GRFS or REPL?
By revenue growth (latest reported year), ADMA Biologics, Inc.
(ADMA) is pulling ahead at 19. 6% versus 0. 2% for Grifols, S. A. (GRFS). On earnings-per-share growth, the picture is similar: Grifols, S. A. grew EPS 147. 8% year-over-year, compared to -25. 9% for ADMA Biologics, Inc.. Over a 3-year CAGR, ADMA leads at 49. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — KLRS or ADMA or GRFS or REPL?
ADMA Biologics, Inc.
(ADMA) is the more profitable company, earning 28. 8% net margin versus 0. 0% for Replimune Group, Inc. — meaning it keeps 28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 37. 5% versus 0. 0% for REPL. At the gross margin level — before operating expenses — ADMA leads at 57. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is KLRS or ADMA or GRFS or REPL more undervalued right now?
On forward earnings alone, Grifols, S.
A. (GRFS) trades at 8. 9x forward P/E versus 9. 9x for ADMA Biologics, Inc. — 1. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for KLRS: 331. 2% to $18. 67.
08Which pays a better dividend — KLRS or ADMA or GRFS or REPL?
In this comparison, GRFS (2.
7% yield) pays a dividend. KLRS, ADMA, REPL do not pay a meaningful dividend and should not be held primarily for income.
09Is KLRS or ADMA or GRFS or REPL better for a retirement portfolio?
For long-horizon retirement investors, Grifols, S.
A. (GRFS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 99), 2. 7% yield). Both have compounded well over 10 years (GRFS: -44. 2%, ADMA: +15. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between KLRS and ADMA and GRFS and REPL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: KLRS is a small-cap quality compounder stock; ADMA is a small-cap high-growth stock; GRFS is a small-cap deep-value stock; REPL is a small-cap quality compounder stock. GRFS pays a dividend while KLRS, ADMA, REPL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.